Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ced/llad067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.
Arch Dermatol Res
January 2025
Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA.
Background: Celiac disease (CeD) has shown an association with autoimmune disorders including vitiligo and alopecia areata (AA). Ritlecitinib, a JAK3 and TEC kinase family inhibitor, has been approved for treatment of patients with AA and is in late-stage development for vitiligo. Ritlecitinib inhibits cytotoxic T cells, NK cells, and B cells which play a role in the pathogenesis of CeD.
View Article and Find Full Text PDFMolecular monitoring of short- and long-term transcriptional effects of hair growth stimulating agents.
PLoS One
December 2024
Institute of Human Genetics, School of Medicine & University Hospital Bonn, University of Bonn, Bonn, Germany.
Male-pattern hair loss (MPHL) is the most common form of hair loss in humans. Limited treatment options exist, which are not curative and vary in efficacy and invasiveness. Therapeutic and cosmetic hair growth stimulating agents that alleviate hair loss at a low risk of side effects are therefore of interest.
View Article and Find Full Text PDFA scoping review of alopecia areata and its relationship to COVID-19 vaccinations.
Arch Dermatol Res
December 2024
Albert Einstein College of Medicine, Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
In response to the COVID-19 pandemic several vaccines were produced, including novel mRNA and viral vector-based vaccines. Though COVID-19 had its own associated dermatological sequelae, the vaccines were associated with a new set of cutaneous side effects, including hypersensitivity reactions, vasculitis, and autoimmune-mediated reactions. Notably, alopecia areata (AA) was reported in several patients closely following a COVID-19 vaccine, especially in those with a personal or family history of AA.
View Article and Find Full Text PDFExpanding the Clinical and Mutational Spectrum of Biallelic POC1A Variants: Characterization of Four Patients and a Comprehensive Review of POC1A-Related Phenotypes.
Clin Genet
December 2024
Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
SOFT syndrome (SOFTS) is an autosomal recessive disorder caused by biallelic POC1A variants, characterized by short stature, distinctive facial features, onychodysplasia, and hypotrichosis. To date, 21 pathogenic POC1A variants have been reported in 26 families. This study aims to broaden the phenotypic and genotypic spectrum of SOFTS with emphasis on the long-term effects of growth hormone (GH) therapy.
View Article and Find Full Text PDFALOPECIA AREATA PROFILING SHOWS LNCRNAS REGULATE THE SUPPRESSED EXPRESSION OF KERATIN.
Georgian Med News
September 2024
Deparment of Dermatology, Lanzhou University Second Hospital, Lanzhou Gansu 730030, China.
Background: Alopecia areata (AA) is one of the most common autoimmune hair diseases. Long non-coding RNAs (lncRNAs) have been shown to be involved in the pathophysiological progression of a variety of diseases; however, how lncRNAs are involved in the pathogenesis of alopecia areata is not fully understood.
Objective: In order to study the differential expression profiles of mRNA and lncRNA in patients with alopecia areata and provide experimental basis for the diagnosis and treatment of alopecia areata.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!